NCT00000231

Brief Summary

The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 1992

Completed
7.6 years until next milestone

First Submitted

Initial submission to the registry

September 20, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 21, 1999

Completed
Last Updated

August 17, 2005

Status Verified

March 1, 1994

First QC Date

September 20, 1999

Last Update Submit

August 16, 2005

Conditions

Opioid-Related Disorders

Outcome Measures

Primary Outcomes (6)

  • Drug use

  • Retention

  • Weeks abstinent

  • Weeks continuous abstinence

  • Overall treatment outcome

  • Naltrexone consumption

Interventions

BuprenorphineDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Please contact site for information.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Treatment Research Center

Burlington, Vermont, 05401, United States

Location

Related Publications (1)

  • Bunyoz KI, Tsikandylakis G, Mortensen K, Gromov K, Mohaddes M, Malchau H, Troelsen A. No difference in whole-blood metal ions between 32-mm and 36- to 44-mm femoral heads in metal-on-polyethylene total hip arthroplasty: a 2-year report from a randomised control trial. Hip Int. 2023 Mar;33(2):184-192. doi: 10.1177/11207000211022623. Epub 2021 Jun 8.

    PMID: 34102902DERIVED

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

Buprenorphine

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Warren Bickel, Ph.D.

    University of Vermont

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 2
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

September 20, 1999

First Posted

September 21, 1999

Study Start

February 1, 1992

Last Updated

August 17, 2005

Record last verified: 1994-03

Locations

US(1)